Article
Oncology
Pat Gulhati, Ronald A. DePinho
Summary: Modulating T cell immune checkpoints and inhibiting chemokine receptors on myeloid-derived suppressor cells can change the highly suppressive tumor immune microenvironment in PDAC and lead to long-lasting complete responses in a mouse model. These findings offer a testable clinical treatment strategy for PDAC in humans.
Article
Biochemistry & Molecular Biology
Jae-young Lee, Hyun-Jung Sohn, Chang-Hyun Kim, Tai-Gyu Kim, Hyun Soo Lee
Summary: This study confirmed the immunosuppressive effect of human cord blood MDSCs on corneal allograft models. Local and systemic MDSC administration inhibited the maturation of dendritic cells and the differentiation of Th1 cells, while reducing the infiltration of inflammatory cells and angiogenesis. The results suggest that CB-MDSCs have therapeutic potential for preventing corneal allograft rejection.
Review
Medicine, Research & Experimental
Anik Pramanik, Sankar Bhattacharyya
Summary: The MDSC population in the tumor microenvironment plays a crucial role in tumor immune evasion and cancer progression by disrupting antitumor T cell activity and potentially affecting other immune cell functions.
Article
Multidisciplinary Sciences
Yuen Ping Chong, Evelyn Priya Peter, Feon Jia Ming Lee, Chu Mun Chan, Shereen Chai, Lorni Poh Chou Ling, Eng Lai Tan, Sook Han Ng, Atsushi Masamune, Siti Aisyah Abd Ghafar, Norsharina Ismail, Ket Li Ho
Summary: Pancreatic cancer cells and pancreatic stellate cells together form the immunosuppressive tumor microenvironment of pancreatic cancer. This study found that co-culture of these two cell types resulted in a reduction in lymphocyte population. Proteomic analysis revealed differentially expressed proteins in two different stages of tumor-derived PCC lines. Additionally, it was found that the conditioned medium containing proteins secreted by PCC and/or PSC enhanced the viability of lymphocyte subtypes, while CM-induced MDSCs decreased the viability of certain T cells.
SCIENTIFIC REPORTS
(2022)
Review
Medicine, General & Internal
Suncica Kapor, Juan F. Santibanez
Summary: This review discusses the main features of MDSCs and MSCs in myeloid malignancies, revealing that MDSCs are elevated in numbers and exhibit strong immunosuppressive capabilities, while MSCs not only have immunosuppressive properties but also regulate the growth, apoptosis, and chemotherapy resistance of myeloid leukemia cells.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Chemistry, Multidisciplinary
Xinghang Dai, Long Ren, Mengxi Liu, Hao Cai, Hu Zhang, Qiyong Gong, Zhongwei Gu, Kui Luo
Summary: MDSCs have been explored as an important immunotherapeutic target in cancer immunology, and nanomedicines have shown potential in reversing immunosuppressive tumors into immunoresponsive ones to enhance therapeutic efficacy.
Article
Pharmacology & Pharmacy
Mingjin Wang, Weida Wang, Shen You, Zhenyan Hou, Ming Ji, Nina Xue, Tingting Du, Xiaoguang Chen, Jing Jin
Summary: Glioblastoma (GBM) is a highly aggressive and lethal brain tumor with an immunosuppressive tumor microenvironment (TME). Myeloid-derived suppressor cells (MDSCs) play a crucial role in suppressing antitumor immunity in this environment. Lipometabolism is closely related to the function of myeloid cells. The study shows that acetyl-CoA acetyltransferase 1 (ACAT1), a key enzyme of fatty acid oxidation (FAO) and ketogenesis, is significantly downregulated in the infiltrated MDSCs in GBM patients. Depletion of ACAT1 in mice resulted in the accumulation of MDSCs and increased tumor progression, likely due to elevated secretion of C-X-C motif ligand 1 (CXCL1) by macrophages (M4). These findings suggest that ACAT1 could be a promising drug target for GBM by regulating the function of MDSCs in the TME.
ACTA PHARMACEUTICA SINICA B
(2023)
Review
Oncology
Peng Dong, Yu Yan, Yujun Fan, Hui Wang, Danzhu Wu, Liyuan Yang, Junpeng Zhang, Xiaoyang Yin, Yajuan Lv, Jiandong Zhang, Yuzhu Hou, Fengjun Liu, Xinshuang Yu
Summary: Pancreatic cancer has a high mortality rate and early symptoms are difficult to detect, leading to a late-stage diagnosis for most patients. Current conventional treatments have limited efficacy, and the tumor microenvironment plays a crucial role in tumor progression. Myeloid-derived suppressor cells are key components in the tumor microenvironment and targeting them is important for effective treatment.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT
(2022)
Article
Medicine, Research & Experimental
Keywan Mortezaee
Summary: Myeloid-derived suppressor cells (MDSCs) are a group of immature immune cells that significantly increase in cancer patients, releasing factors that impact tumor-related events such as metastasis and immune evasion, and can serve as an indicator of tumor prognosis. They can be targeted in combination with current immunotherapies to enhance the immune system's response against tumors.
Review
Pharmacology & Pharmacy
Jie Zhao, Yiting Dong, Yundi Zhang, Jie Wang, Zhijie Wang
Summary: This article systematically reviews the complex functions of tumor-associated myeloid cells (TAMCs) in tumor development and immune response, and summarizes clinical strategies to overcome resistance to immunotherapy and future research prospects.
ADVANCED DRUG DELIVERY REVIEWS
(2022)
Review
Cell Biology
Vaishali Bhardwaj, Stephen M. M. Ansell
Summary: Myeloid-derived suppressor cells (MDSCs) are immunosuppressive cells composed of pathologically activated neutrophils and monocytes that negatively regulate the immune response to cancer and chronic infections. They exhibit distinct characteristics and exert strong immunosuppressive effects on T-cells and other immune cells, making them a major obstacle to cancer immunotherapies. However, the clinical outcomes of targeting MDSCs in hematological malignancies, particularly B-cell malignancies, still require further exploration. This review provides a comprehensive summary of the complex biology and immunosuppressive pathways of MDSCs, with a focus on their role in modulating T-cell function in hematological malignancies, and discusses the challenges, therapeutic strategies, and clinical relevance of targeting MDSCs in these diseases.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Kai Li, Houhui Shi, Benxia Zhang, Xuejin Ou, Qizhi Ma, Yue Chen, Pei Shu, Dan Li, Yongsheng Wang
Summary: MDSCs are a group of immunosuppressive cells that play a crucial role in tumor progression, affecting tumor development through various pathways and interfering with the efficacy of current anti-tumor therapies. Targeting MDSCs is a promising strategy for future cancer treatment.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2021)
Review
Immunology
Zhuang Chen, Rui Yuan, Shengyun Hu, Weitang Yuan, Zhenqiang Sun
Summary: This review provides a comprehensive description of the characteristics, functions, and mechanisms of myeloid-derived suppressor cell exosomes (MDSCs-Exos) in tumor immunity. MDSCs-Exos show similar immunosuppressive, angiogenesis, and metastatic effects as parental MDSCs. Immunotherapy targeting MDSCs-Exos has great potential in both cancer and non-cancerous diseases.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Pharmacology & Pharmacy
Shweta Joshi, Andrew Sharabi
Summary: This review discusses the role of MDSCs in tumor growth, their interaction with NK cells, and the impact on NK cell-based immunotherapies, presenting strategies to enhance NK cell cytotoxicity.
PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Oncology
Ting Zhao, Sheng Liu, Nasser H. Hanna, Shadia Jalal, Xinchun Ding, Jun Wan, Cong Yan, Hong Du
Summary: Understanding the mechanisms of MDSC biogenesis, particularly the role of LAL, can facilitate the diagnosis and prognosis of cancer, as well as the development of targeted immunotherapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Dapeng Zhang, Lihua Cui, Shu Shun Li, Feng Wang
Article
Obstetrics & Gynecology
Yu Zhou, Yuanyuan Ren, Lihua Cui, Zongjin Li, Yingjun Zhu, Wanjun Lin, Yuebing Wang
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
(2014)
Editorial Material
Obstetrics & Gynecology
Lihua Cui, Yuanyuan Ren, Hao Yin, Yuebing Wang, Dong Li, Meng Liu, Yingjun Zhu, Wanjun Lin, Xiang D. Tang, Yu Gui, Xi-Long Zheng
FERTILITY AND STERILITY
(2011)
Article
Obstetrics & Gynecology
Yuanyuan Ren, Hao Yin, Ruijuan Tian, Lihua Cui, Yingjun Zhu, Wanjun Lin, Xiang D. Tang, Yu Gui, Xi-Long Zheng
FERTILITY AND STERILITY
(2011)
Article
Medicine, Research & Experimental
Cai-Xia Li, Li-Hua Cui, Yu-Zhen Zhuo, Jian-Gong Hu, Nai-qiang Cui, Shu-Kun Zhang
Article
Multidisciplinary Sciences
Jingrui Bai, Hongbin Liu, Donghua Li, Lihua Cui, Xianzhong Wu
Article
Biochemistry & Molecular Biology
Li-Hua Cui, Cai-Xia Li, Yu-Zhen Zhuo, Lei Yang, Nai-Qiang Cui, Shu-Kun Zhang
CHEMICO-BIOLOGICAL INTERACTIONS
(2019)
Article
Medicine, Research & Experimental
Lihua Cui, Caixia Li, Ge Gao, Yuzhen Zhuo, Lei Yang, Naiqiang Cui, Shukun Zhang
Article
Medicine, Research & Experimental
Yuzhen Zhuo, Dihua Li, Lihua Cui, Caixia Li, Shukun Zhang, Qi Zhang, Lanqiu Zhang, Ximo Wang, Lei Yang
BIOMEDICINE & PHARMACOTHERAPY
(2019)
Article
Medicine, Research & Experimental
Lihua Cui, Caixia Li, Yuzhen Zhuo, Lei Yang, Naiqiang Cui, Yuhong Li, Shukun Zhang
BIOMEDICINE & PHARMACOTHERAPY
(2020)
Article
Oncology
Cai-Xia Li, Li-Hua Cui, Lan-Qiu Zhang, Lei Yang, Yu-Zhen Zhuo, Nai-Qiang Cui, Shu-Kun Zhang
Summary: Activation of the NLRP3 inflammasome is directly involved in the activation of Pancreatic stellate cells in vivo and in vitro, and inhibiting NLRP3 suppresses the activation of PSCs through the TGF-β1/Smad3 pathway.
EXPERIMENTAL CELL RESEARCH
(2021)
Article
Pharmacology & Pharmacy
Lihua Cui, Caixia Li, Ye Shang, Dihua Li, Yuzhen Zhuo, Lei Yang, Naiqiang Cui, Yuhong Li, Shukun Zhang
Summary: Chaihu Guizhi Ganjiang Decoction (CGGD) showed effects in alleviating pancreatic damage, reducing collagen deposition, and inhibiting pancreatic stellate cell (PSC) activation in a rat model of chronic pancreatitis. By suppressing autophagy in PSCs through the JNK/mTOR signaling pathway, CGGD attenuated pancreatic fibrosis and PSC activation.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Biology
Lihua Cui, Yuanyuan Jin, Sen Zou, Jing Xun, Xiangyang Yu, Qi Zhang, Zhaoyong Yang
Summary: The study demonstrates that hPRDX5 can effectively suppress pancreatic cancer growth and increase the population of immune cells, suggesting its potential as an immunotherapy candidate.
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
(2022)
Article
Integrative & Complementary Medicine
Jing Yang, Feng Wang, Xijuan Chen, Shuai Qiu, Lihua Cui, Lijuan Hu
AMERICAN JOURNAL OF CHINESE MEDICINE
(2019)